title: [Ibandronate].
abstract: Osteoporosis is chronic bone disorder that require persistent treatment. Bone fracture is the final outcome of OP and early diagnosis, active prevention, treatment and improvement of the patient adherence to treatment are needed. Ibandronate is a potent, nitrogen-containing bisphosphonate specifically developed for once-monthly oral and three-monthly administration with the same anti-resorptive efficacy. Ibandronate reduce vertebral fracture risk 50-60%, increase spine and hip BMD, 6% and 3%, significantly decrease biochemical markers of bone turn-over without histomorphometric changes of bone. There is strong patient preference for once-monthly regimen and the favourable impact on therapeutic adherence. Intravenous ibandronate formulation is indicated for all patients who are unable to take oral medicine. Adverse events are infrequent, short duration and reversibile.
authors.affiliation: Klinika za reumatske bolesti i rehabilitaciju, Klinicki bolnicki centar Zagreb, Kispatićeva 12, 10000 Zagreb.
authors.forename: Durdica
authors.initials: D
authors.lastname: Babić-Naglic
authors.forename: Simeon
authors.initials: S
authors.lastname: Grazio
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D000077557:Ibandronic Acid; D010024:Osteoporosis / Q000188:drug therapy*
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077557:Ibandronic Acid